Skip to main content
Top
Published in: Annals of Surgical Oncology 13/2019

01-12-2019 | Thyroid Cancer | Endocrine Tumors

A Novel N Staging System for Predicting Survival in Patients with Medullary Thyroid Cancer

Authors: Lili Chen, MM, Kai Qian, MD, Kai Guo, MM, Xiaoke Zheng, MM, Wenyu Sun, MM, Tuanqi Sun, MD, Yunjun Wang, MD, Duanshu Li, MM, Yi Wu, MD, Qinghai Ji, MD, Zhuoying Wang, MD, PhD

Published in: Annals of Surgical Oncology | Issue 13/2019

Login to get access

Abstract

Introduction

Despite the crucially prognostic value of lymph node metastasis (LNM) in patients with medullary thyroid cancer (MTC), only the LNM compartment alone was reflected in the 8th edition of the American Joint Committee on Cancer (AJCC) system.

Objective

This study aimed to incorporate the metastatic lymph node number and metastatic lymph node ratio to generate a more accurate and appropriate N staging system for patients with MTC based on recursive partitioning analysis.

Design, Setting, and Patients

Two cohorts were included in the analysis, including 1374 MTC patients from the Surveillance, Epidemiology, and End Results database as the derivation cohort, and 164 patients from Fudan University Shanghai Cancer Center as the validation cohort. The predictive performance of the alternative proposed N staging system was compared with that of the 8th AJCC system by using the Harrell concordance index (C-index) and the area under the receiver operating characteristic curve (AUC).

Results

In the derivation cohort, the C-index and the AUC at 10 years were 0.778 and 0.789, respectively, for the novel N staging system, and 0.749 and 0.741, respectively, for the 8th AJCC N staging system. Similar trends were also observed in the validation cohort. The proposed N staging system had a better prognostic performance.

Conclusion

With some improvements, the novel N staging system for MTC suggested from this research may be assessed for potential adoption in the next edition of the AJCC N staging system.
Literature
1.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians. 2019;69(1):7-34. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians. 2019;69(1):7-34.
2.
go back to reference Brose MS, Bible KC, Chow LQM, et al. Management of treatment-related toxicities in advanced medullary thyroid cancer. Cancer Treat Rev. 2018;66:64–3.CrossRef Brose MS, Bible KC, Chow LQM, et al. Management of treatment-related toxicities in advanced medullary thyroid cancer. Cancer Treat Rev. 2018;66:64–3.CrossRef
3.
go back to reference Ernani V, Kumar M, Chen AY, Owonikoko TK. Systemic treatment and management approaches for medullary thyroid cancer. Cancer Treat Rev. 2016;50:89–8.CrossRef Ernani V, Kumar M, Chen AY, Owonikoko TK. Systemic treatment and management approaches for medullary thyroid cancer. Cancer Treat Rev. 2016;50:89–8.CrossRef
4.
go back to reference Wells SA Jr, Asa SL, Dralle H, et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–10.CrossRef Wells SA Jr, Asa SL, Dralle H, et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–10.CrossRef
5.
go back to reference Castinetti F, Waguespack SG, Machens A, et al. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes Endocrinol. 2019;7(3):213–20.CrossRef Castinetti F, Waguespack SG, Machens A, et al. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes Endocrinol. 2019;7(3):213–20.CrossRef
6.
go back to reference Accardo G, Conzo G, Esposito D, et al. Genetics of medullary thyroid cancer: an overview. Int J Surg. 2017;41:S2–S6.CrossRef Accardo G, Conzo G, Esposito D, et al. Genetics of medullary thyroid cancer: an overview. Int J Surg. 2017;41:S2–S6.CrossRef
7.
go back to reference Bae YJ, Schaab M, Kratzsch J. Calcitonin as biomarker for the medullary thyroid carcinoma. In: Raue F (ed). Medullary thyroid carcinoma: biology—management—treatment. Springer, Cham; 2015, pp. 117–137.CrossRef Bae YJ, Schaab M, Kratzsch J. Calcitonin as biomarker for the medullary thyroid carcinoma. In: Raue F (ed). Medullary thyroid carcinoma: biologymanagementtreatment. Springer, Cham; 2015, pp. 117–137.CrossRef
8.
go back to reference Cabanillas ME, Houston MR, Hu MI, et al. Prognostic significance of circulating RET M918T mutated tumor DNA in patients with advanced medullary thyroid carcinoma. J Clin Endocrinol Metab. 2017;102(9):3591–9.CrossRef Cabanillas ME, Houston MR, Hu MI, et al. Prognostic significance of circulating RET M918T mutated tumor DNA in patients with advanced medullary thyroid carcinoma. J Clin Endocrinol Metab. 2017;102(9):3591–9.CrossRef
9.
go back to reference Berg AN, Seethala RR. The American Joint Committee on cancer eighth edition: changes in thyroid carcinoma staging and an update on reporting. AJSP Rev Rep. 2018;23(3):145–8. Berg AN, Seethala RR. The American Joint Committee on cancer eighth edition: changes in thyroid carcinoma staging and an update on reporting. AJSP Rev Rep. 2018;23(3):145–8.
10.
go back to reference Ding N, Pang Z, Zhang X, et al. Prognostic and predictive effects of positive lymph node number or ratio in NSCLC. Sci Rep. 2017;7(1):584.CrossRef Ding N, Pang Z, Zhang X, et al. Prognostic and predictive effects of positive lymph node number or ratio in NSCLC. Sci Rep. 2017;7(1):584.CrossRef
11.
go back to reference Kang SI, Kim D-W, Shin E, et al. Clinical significance of lymph node metastasis in the mesentery of the terminal ileum in patients with right-sided colon tumors at different locations. Dis Colon Rectum. 2018;61(6):692–7.CrossRef Kang SI, Kim D-W, Shin E, et al. Clinical significance of lymph node metastasis in the mesentery of the terminal ileum in patients with right-sided colon tumors at different locations. Dis Colon Rectum. 2018;61(6):692–7.CrossRef
12.
go back to reference Ho AS, Kim S, Tighiouart M, et al. Metastatic lymph node burden and survival in oral cavity cancer. J Clin Oncol. 2017;35(31):3601–9.CrossRef Ho AS, Kim S, Tighiouart M, et al. Metastatic lymph node burden and survival in oral cavity cancer. J Clin Oncol. 2017;35(31):3601–9.CrossRef
13.
go back to reference Ho AS, Kim S, Tighiouart M, et al. Association of quantitative metastatic lymph node burden with survival in hypopharyngeal and laryngeal cancer. JAMA Oncol. 2018;4(7):985–9.CrossRef Ho AS, Kim S, Tighiouart M, et al. Association of quantitative metastatic lymph node burden with survival in hypopharyngeal and laryngeal cancer. JAMA Oncol. 2018;4(7):985–9.CrossRef
14.
go back to reference Machens A, Lorenz K, Dralle HJE. Histology-proven recurrence in the lateral or central neck after systematic neck dissection for medullary thyroid cancer. Endocrine. 2018;61(3):428–9.CrossRef Machens A, Lorenz K, Dralle HJE. Histology-proven recurrence in the lateral or central neck after systematic neck dissection for medullary thyroid cancer. Endocrine. 2018;61(3):428–9.CrossRef
15.
go back to reference Machens A, Dralle H. Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system. Ann Surg. 2013;257(2):323–9.CrossRef Machens A, Dralle H. Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system. Ann Surg. 2013;257(2):323–9.CrossRef
16.
go back to reference Adam MA, Pura J, Goffredo P, et al. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol. 2015;33(21):2370–5.CrossRef Adam MA, Pura J, Goffredo P, et al. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol. 2015;33(21):2370–5.CrossRef
17.
go back to reference Hothorn T, Hornik K, Zeileis A. Unbiased recursive partitioning: a conditional inference framework. J. Comput. Graph. Stat. 2006;15(3):651–74.CrossRef Hothorn T, Hornik K, Zeileis A. Unbiased recursive partitioning: a conditional inference framework. J. Comput. Graph. Stat. 2006;15(3):651–74.CrossRef
18.
go back to reference Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why? Thyroid. 2017;27(6):751–6.CrossRef Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why? Thyroid. 2017;27(6):751–6.CrossRef
19.
go back to reference Nixon IJ, Shaha AR. Management of regional nodes in thyroid cancer. Oral Oncology. 2013;49(7):671–5.CrossRef Nixon IJ, Shaha AR. Management of regional nodes in thyroid cancer. Oral Oncology. 2013;49(7):671–5.CrossRef
20.
go back to reference Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. J Natl Compr Canc Netw. 2010;8(5):549–56.CrossRef Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. J Natl Compr Canc Netw. 2010;8(5):549–56.CrossRef
21.
go back to reference Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary Thyroid Carcinoma. Clin Oncol. 2010;22(6):475–85.CrossRef Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary Thyroid Carcinoma. Clin Oncol. 2010;22(6):475–85.CrossRef
22.
go back to reference Qian K, Sun W, Guo K, et al. The number and ratio of positive lymph nodes are independent prognostic factors for patients with major salivary gland cancer: results from the surveillance, epidemiology, and end results dataset. Eur J Surg Oncol. 2019;45(6):1025–32.CrossRef Qian K, Sun W, Guo K, et al. The number and ratio of positive lymph nodes are independent prognostic factors for patients with major salivary gland cancer: results from the surveillance, epidemiology, and end results dataset. Eur J Surg Oncol. 2019;45(6):1025–32.CrossRef
23.
go back to reference Tang X, Chen Y, Guo L, Zhang J, Wang C. Prognostic significance of metastatic lymph node number, ratio and station in gastric neuroendocrine carcinoma. J Gastrointest Surg. 2015;19(2):234–41.CrossRef Tang X, Chen Y, Guo L, Zhang J, Wang C. Prognostic significance of metastatic lymph node number, ratio and station in gastric neuroendocrine carcinoma. J Gastrointest Surg. 2015;19(2):234–41.CrossRef
24.
go back to reference Zhou Y-Y, Du X-J, Zhang C-H, et al. Comparison of three lymph node staging schemes for predicting the outcome in patients with small bowel adenocarcinoma: a population-based cohort and international multicentre cohort study. EBioMedicine. 2019;41:276–85.CrossRef Zhou Y-Y, Du X-J, Zhang C-H, et al. Comparison of three lymph node staging schemes for predicting the outcome in patients with small bowel adenocarcinoma: a population-based cohort and international multicentre cohort study. EBioMedicine. 2019;41:276–85.CrossRef
25.
go back to reference Randle RW, Balentine CJ, Leverson GE, et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery. 2017;161(1):137–46.CrossRef Randle RW, Balentine CJ, Leverson GE, et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery. 2017;161(1):137–46.CrossRef
26.
go back to reference Kuo EJ, Sho S, Li N, Zanocco KA, Yeh MW, Livhits MJ. Risk factors associated with reoperation and disease-specific mortality in patients with medullary thyroid carcinoma. JAMA Surg. 2018;153(1):52–9.CrossRef Kuo EJ, Sho S, Li N, Zanocco KA, Yeh MW, Livhits MJ. Risk factors associated with reoperation and disease-specific mortality in patients with medullary thyroid carcinoma. JAMA Surg. 2018;153(1):52–9.CrossRef
27.
go back to reference Meng K, Luo H, Chen H, Guo H, Xia W. Prognostic value of numbers of metastatic lymph node in medullary thyroid carcinoma: a population-based study using the SEER 18 database. Medicine (Baltimore). 2019;98(1):e13884.CrossRef Meng K, Luo H, Chen H, Guo H, Xia W. Prognostic value of numbers of metastatic lymph node in medullary thyroid carcinoma: a population-based study using the SEER 18 database. Medicine (Baltimore). 2019;98(1):e13884.CrossRef
28.
go back to reference Tingyin Jiang CH, Yuan X. Ratio of positive lymph nodes: the prognostic value in stage IV thyroid cancer. Oncotarget. 2017;8(45):79462–8. Tingyin Jiang CH, Yuan X. Ratio of positive lymph nodes: the prognostic value in stage IV thyroid cancer. Oncotarget. 2017;8(45):79462–8.
Metadata
Title
A Novel N Staging System for Predicting Survival in Patients with Medullary Thyroid Cancer
Authors
Lili Chen, MM
Kai Qian, MD
Kai Guo, MM
Xiaoke Zheng, MM
Wenyu Sun, MM
Tuanqi Sun, MD
Yunjun Wang, MD
Duanshu Li, MM
Yi Wu, MD
Qinghai Ji, MD
Zhuoying Wang, MD, PhD
Publication date
01-12-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07871-1

Other articles of this Issue 13/2019

Annals of Surgical Oncology 13/2019 Go to the issue